Cadonilimab + Chemotherapy for Stomach Cancer

(G/GEJ Trial)

This trial tests a new treatment combination for stomach cancer that has spread or cannot be removed by surgery. The study evaluates the effectiveness of the experimental drug cadonilimab combined with chemotherapy, compared to chemotherapy alone or with another drug, nivolumab. It aims to determine which treatment helps patients live longer. Eligible participants have stomach cancer that has not been treated with systemic therapy and cannot be surgically removed. As a Phase 3 trial, this study represents the final step before FDA approval, providing patients an opportunity to access potentially effective treatments early.

Earlier studies tested cadonilimab to assess its safety for treating advanced stomach cancer. These studies aimed to evaluate how well patients tolerate cadonilimab as a first-line treatment. Although detailed data from these studies is unavailable, cadonilimab's approval for other uses suggests its safety is generally well-known. This indicates thorough testing has confirmed its safety for patients, even though specific details like side effects weren't provided in the sources.

Cadonilimab is unique because it's an innovative immunotherapy that targets both PD-1 and CTLA-4 pathways, aiming to enhance the immune system's ability to attack stomach cancer cells. Traditional treatments often revolve around chemotherapy alone, like the CAPOX regimen, which combines oxaliplatin and capecitabine. Researchers are excited about Cadonilimab because its dual-action mechanism could potentially offer a more robust response against cancer. Additionally, when combined with chemotherapy, it might improve overall survival rates and reduce the cancer's ability to evade the immune system compared to standard treatments.

This trial will evaluate the effectiveness of cadonilimab combined with chemotherapy for stomach cancer. Studies have shown that cadonilimab with chemotherapy can significantly improve outcomes for stomach cancer patients, reducing the risk of death by 33% compared to PD-1 inhibitors. Another study found that cadonilimab with chemotherapy has strong anti-tumor effects and is generally safe. In this trial, one group will receive cadonilimab or a placebo with the CAPOX regimen, while another group will receive the CAPOX regimen with or without nivolumab. Research has shown that nivolumab, when used with chemotherapy, helps patients with advanced stomach cancer live longer. These findings suggest that both cadonilimab and nivolumab, when combined with chemotherapy, could be effective treatments for stomach cancer.⁶⁷⁸⁹¹⁰